Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteopenia or Osteoporosis Clear all
Completed No phase listed Observational

Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability

NCT05721898
View directory record Official record
Conditions
Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk, Osteoporotic Fractures, Fragility Fracture, Bone Fracture
Interventions
Cortical Bone Mechanics Technology
Diagnostic Test
Lead sponsor
Ohio University
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
394 participants
Timeline
2022 – 2023
U.S. locations
5
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00436917
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid, Letrozole as adjuvant therapy
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate Cancer

NCT00003903
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
management of therapy complications
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2013 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 4 Interventional

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

NCT02598453
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:34 PM EDT
Completed No phase listed Observational

Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer

NCT00005605
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

NCT00132808
View directory record Official record
Conditions
Osteopenia
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

NCT00577850
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
risedronate, alendronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Validating Osteoporosis Detection in Rho AI Software

NCT06830005
View directory record Official record
Conditions
Osteopenia or Osteoporosis
Interventions
Rho AI software
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jul 23, 2026, 10:34 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636
View directory record Official record
Conditions
Change in Bone Mineral Density, Bone Loss
Interventions
drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
1,536 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
27
States / cities
Phoenix, Arizona • Aurora, Colorado • Boynton Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Hialeah, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

NCT01153425
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Virtual Bone Biopsy, Teriparatide, Zoledronic Acid
Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women

NCT00578981
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
Interventions
Osteoporosis Choice Decision Aid
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 4 Interventional

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

NCT02604836
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
1,711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
142
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer

NCT00088010
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years · Female only
Enrollment
9,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Elk Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy

NCT00050011
View directory record Official record
Conditions
Breast Neoplasms, Osteoporosis
Interventions
Zoledronic Acid, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
43
States / cities
Springdale, Arkansas • Burbank, California • Lafayette, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Jul 23, 2026, 10:34 PM EDT